Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The pharmaceutical industry has recently taken steps to make clinical trial data more accessible. But for there to be meaningful transparency, governments—not drug companies—should set the terms of disclosure.
Regenerative medicine may enable replacement of damaged or diseased tissues. But its clinical success will require deeper understanding of the basic biology of the stem cell niche and coordination between stem cell biologists and those in other fields.
Two years ago, Gyanendra Nath Singh was tasked with overseeing India's drug regulatory agency. Despite the US having temporarily suspended a suite of trials in India and banned drug imports from several manufacturers there over the last couple of years, Singh says progress is being made. Killugudi Jayaraman reports.